Home › Funds › Atle Fund Management AB › SMMT
Atle Fund Management AB position in SMMT
SUMMIT THERAPEUTICS INC · Health Care
Atle Fund Management AB reported holding 184,687 shares of SMMT (SUMMIT THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$3.1M, representing 0.84% of its reported portfolio and ranking #33 among its reported holdings. Atle Fund Management AB has disclosed SMMT holdings in 6 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Atle Fund Management AB's SMMT position evolved
Atle Fund Management AB first disclosed a stake in SMMT in Q3 2024 at 86,013 shares (US$1.9M). The position peaked in Q3 2026 at 184,687 shares, worth US$3.1M. Across 6 filings, Atle Fund Management AB increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 184,687 shares valued at US$3.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 86.01K | $1.88M | New |
| Q4 2024 | 101.18K | $1.31M | Add |
| Q1 2025 | 105.08K | $2.03M | Add |
| Q2 2025 | 92.74K | $1.97M | Reduce |
| Q3 2025 | 92.74K | $203.40K | Hold |
| Q3 2026 | 184.69K | $3.12M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SMMT and 13F data
SMMT (SUMMIT THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in SMMT — the largest reported positions include BAKER BROS. ADVISORS LP (US$477.7M), Logos Global Management LP (US$19.7M), Octagon Capital Advisors LP (US$18.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SMMT
- BAKER BROS. ADVISORS LP 32.79M sh · $477.70M · Q2 2026
- Logos Global Management LP 1.35M sh · $19.67M · Q2 2026
- Octagon Capital Advisors LP 1.25M sh · $18.21M · Q2 2026
- Kynam Capital Management, LP 1.20M sh · $17.48M · Q2 2026
- APEIRON CAPITAL Ltd 961.87K sh · $14.01M · Q2 2026
- Elmind Capital, LP 493.82K sh · $7.19M · Q2 2026
More on Atle Fund Management AB
FAQ
How long has Atle Fund Management AB held SMMT?
Atle Fund Management AB has disclosed SMMT holdings in 6 of the last 9 reported quarters, going back to Q3 2024.
What is Atle Fund Management AB's current position in SMMT?
As of Q3 2026, Atle Fund Management AB holds 184.69K shares of SMMT (SUMMIT THERAPEUTICS INC), valued at $3.12M, representing 0.84% of its reported portfolio and ranking #33.
Has Atle Fund Management AB been buying or selling SMMT?
In the latest 13F filing (Q3 2026), Atle Fund Management AB newly opened its position in SMMT. The position peaked in Q3 2026 at 184.69K shares.
Which other funds hold SMMT?
Other major institutional holders of SMMT include BAKER BROS. ADVISORS LP, Logos Global Management LP, Octagon Capital Advisors LP, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.